KH-631

N/A

Report date: 2026/01/07 13:36:11

Base Information

Drug NameKH-631
Drug Alias NameKH-631KH631
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV8 vector
Mechanisms of ActionGene transference
TargetsVascular endothelial growth factor
Therapy Area/IndicationsDiabetic macular oedemaWet age-related macular degenerationMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesChengdu Kanghong Pharmaceutical Group Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesChengdu Origen Biotechnology Co LtdChengdu Kanghong Pharmaceutical Group Co LtdChengdu Hongji Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaWet age-related macular degenerationMacular Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A